Alcon Inc. ALC
74.12 USD +2.29 (+3.19%)
At closeNov 13, 2026, 4:00 PM EST
74.12 0.00 0.00%
After hours · Nov 13, 4:00 PM ET
72.58 Day range 74.18
61.84 52-week range 87.64
- YTD
- -5.95%
- 1 year
- -5.71%
News
benzinga.com Barclays Maintains Equal-Weight on Alcon, Raises Price Target to $80 Barclays analyst Christopher Pasquale maintains Alcon (NYSE:ALC) with a Equal-Weight and raises the price target from $70 to $80.
benzinga.com Baird Maintains Outperform on Alcon, Lowers Price Target to $87 Baird analyst Jeff Johnson maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $90 to $87.
benzinga.com NVIDIA To $186? Here Are 10 Top Analyst Forecasts For Thursday Analysts cut targets and ratings for General Mills, Redwood Trust and Evgo, while raising targets for Radcom, Royal Caribbean and others.
fool.com Alcon: 3 Key Takeaways for Long-Term Investors Alcon expects full-year net sales growth of approximately 6%. UNITY equipment reached 40% of U.S. teaching hospitals in 2026.
seekingalpha.com Alcon Inc. (ALC) Q3 2026 Earnings Call Transcript Alcon Inc. ( ALC ) Q3 2026 Earnings Call November 11, 2026 8:00 AM EST Company Participants Daniel Cravens - Vice President of Investor Relations David Endicott - CEO & Director Timothy Stonesifer -…
zacks.com ALC's Q3 Earnings Beat, Revenues Miss, '26 Outlook Narrows, Stock Down Alcon's Q3 earnings top estimates as sales miss, margins expand and 2026 growth targets narrow; shares slip after the report.
benzinga.com Implantable Headwinds Clip Alcon Revenue Pace Despite Solid Premium Lens Gains Alcon beats Q3 earnings forecasts despite a slight revenue miss, driven by contact lens gains, surgical IOL pressures, and revised 2026 sales guidance.
benzinga.com Alcon Q3 2026 Earnings Call Transcript Alcon (NYSE:ALC) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
benzinga.com Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Rise as Bessent Urges US-China to ‘De-Risk’— Alcon, CoreWeave, Telefonica Brasil in Focus (UPDATED) U.S. stock futures rose on Wednesday, as the Dow Jones, S&P 500, and Nasdaq 100 indices advanced, following Tuesday's lower close.
benzinga.com Brightview Posts Downbeat Q4 Results, Joins Astronics, Spire Global And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. futures rose, but BrightView plunged 17.7% after missing earnings and sales estimates; Lightwave Logic and others also fell premarket.
reuters.com Alcon shares fall as tighter eye-care market outlook raises growth concerns Alcon shares fall as tighter eye-care market outlook raises growth concerns
zacks.com Alcon (ALC) Reports Q3 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Alcon (ALC) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare…
benzinga.com CORRECTION: Alcon Q3 Adj. EPS $0.91 Beats $0.87 Estimate, Sales $2.717B Miss $2.737B Estimate Alcon (NYSE:ALC) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.87 by 4.6 percent. This is a 15.19 percent increase over earnings of $0.79 per share…
benzinga.com Alcon Narrows FY2026 Adj EPS Guidance from $3.44-$3.53 to $3.44-$3.50 vs $3.44 Est; Narrows FY2026 Sales Guidance from $10.835B-$11.041B to $10.938B vs $11.073B Est Alcon (NYSE:ALC) narrows FY2026 Adj EPS guidance from $3.44-$3.53 to $3.44-$3.50 vs $3.44 analyst estimate. Narrows FY2026 sales outlook from $10.835 billion-$11.041 billion to $10.938 billion vs…
benzinga.com Alcon Q3 Adj. EPS $0.91 Beats $0.87 Estimate, Sales $2.717M Miss $2.737B Estimate Alcon (NYSE:ALC) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.87 by 4.6 percent. This is a 15.19 percent increase over earnings of $0.79 per share…
businesswire.com Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth GENEVA--(BUSINESS WIRE)--Innovation and Product Launch Momentum Drive Alcon's Third-Quarter 2026 Growth.
benzinga.com TransDigm Group, Take-Two And 3 Stocks To Watch Heading Into Tuesday Stocks in focus: TransDigm and Sally Beauty report earnings; Babcock & Wilcox beat sales; Take-Two topped estimates; Alcon reports after close.
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…
businesswire.com Algoma Central Corporation Announces Closing of Over-Allotment Option of Additional Debentures ST. CATHARINES, Ontario--(BUSINESS WIRE)--Algoma Central Corporation (“Algoma”) (TSX:ALC) is pleased to announce that, in connection with its previously announced offering (the “Public Offering”) of…
businesswire.com Algoma Central Corporation Reports Financial Results for the 2026 Third Quarter ST. CATHARINES, Ontario--(BUSINESS WIRE)--Algoma Central Corporation (TSX: ALC) ("Algoma", the "Company") today reported its results for the three and nine months ended September 30, 2026. Algoma…- benzinga.com Keybanc Maintains Overweight on Alcon, Lowers Price Target to $84 Keybanc analyst Brett Fishbin maintains Alcon (NYSE:ALC) with a Overweight and lowers the price target from $88 to $84.
benzinga.com Alcon Acquires Neurotech Pharmaceuticals For $550M Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced it has acquired Neurotech Pharmaceuticals, Inc., a company focused on developing…- benzinga.com Alcon Announces FDA Approval For BRYTLY Redness Relief Eye Drops, Expanding Over The Counter Eye Care Portfolio. One drop works to significantly reduce redness, with results lasting up to 12 hours1Lasts up to 50% longer than Lumify1-2,*Expands Alcon's portfolio of consumer eye care solutions and will be…
benzinga.com Barclays Initiates Coverage On Alcon with Equal-Weight Rating, Announces Price Target of $70 Barclays analyst Christopher Pasquale initiates coverage on Alcon (NYSE:ALC) with a Equal-Weight rating and announces Price Target of $70.
benzinga.com Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
benzinga.com Why Is Netflix Stock Falling on Monday? Netflix Inc. (NASDAQ: NFLX) stock slips as market concerns over third-quarter revenue and earnings guidance outweigh Bill Ackman's new Pershing Square stake.
benzinga.com Bill Ackman’s New Stock Picks Are Here. These ETFs Could Be Worth Watching Bill Ackman's new stock picks include Netflix, Visa and Mastercard. ETF investors can get fresh exposure through VFH, XLC and IAI.
benzinga.com Bill Ackman Lost $400 Million on NFLX Stock in 2022 — Now He’s Back With a 3.15M-Share Bet, Saying Netflix Has ‘Won the Streaming Wars’ (UPDATED) Bill Ackman’s Pershing Square re-enters Netflix with a 3.15M share stake, declaring the streaming wars won after a historic 2022 loss.
benzinga.com JP Morgan Maintains Neutral on Alcon, Raises Price Target to $78.4 JP Morgan analyst David Adlington maintains Alcon (NYSE:ALC) with a Neutral and raises the price target from $77.53 to $78.4.
benzinga.com Mizuho Maintains Outperform on Alcon, Raises Price Target to $85 Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Outperform and raises the price target from $80 to $85.
benzinga.com National CineMedia Posts Downbeat Q2 Results, Joins Borr Drilling, AbCellera Biologics And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures higher, Nasdaq 100 up 150 pts. National CineMedia shares down 16.4% on weak Q2 results and Captivate Holdings acquisition. Other stocks also falling in pre-market trading.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers P3 Health Partners (NASDAQ:PIII) shares increased by 24.1% to $15.92 during Monday's after-market session. The market value of their outstanding shares is at $38.5 million. As per the press…- benzinga.com Alcon Raises FY2026 Adj EPS Guidance from $3.38-$3.47 to $3.44-$3.53 vs $3.41 Est; Widens FY2026 Sales Guidance of $10.835B-$11.041B vs $11.087B Est Alcon (NYSE:ALC) raises FY2026 Adj EPS guidance from $3.38-$3.47 to $3.44-$3.53 vs $3.41 analyst estimate. Widens FY2026 sales outlook from $10.835 billion-$11.041 billion to $10.835 billion-$11.041…
benzinga.com Alcon Q2 Adj. EPS $0.84 Beats $0.75 Estimate, Sales $2.782B Beat $2.769B Estimate Alcon (NYSE:ALC) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.75 by 12 percent. This is a 10.53 percent increase over earnings of $0.76 per share…
benzinga.com S&P 500 Surges To Record Close Following Jobs Data: Investor Sentiment Improves, Fear Index Remains in ‘Greed’ Zone U.S. stocks closed higher, with Nasdaq up 300 points. S&P 500 and Nasdaq rose for the second consecutive week. Fear & Greed index in Greed zone.
benzinga.com Aecom, Alcon And 3 Stocks To Watch Heading Into Monday U.S. stock futures mixed, Aecom and Hawaiian Electric report earnings, Alcon expected to release earnings, Check Cap announces reverse split, Monday.Com expected to post earnings.- benzinga.com Mizuho Maintains Outperform on Alcon, Lowers Price Target to $80 Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $85 to $80.
- benzinga.com Alcon And RxSight Announce A Non-Exclusive Collaboration To Jointly Develop Adjustable Presbyopia-Correcting Intraocular Lenses Alcon (NYSE:ALC), the global leader in eye care dedicated to helping people see brilliantly, and RxSight, Inc. (NASDAQ:RXST), an ophthalmic medical device company dedicated to providing high-quality…
benzinga.com Zoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio? Weak earnings, soft guidance and analyst target cuts triggered sharp selloffs across healthcare, software, networking and industrial stocks last week, led by Zoetis, Insmed and HubSpot.- benzinga.com Barclays Maintains Equal-Weight on Alcon, Lowers Price Target to $78 Barclays analyst Matt Miksic maintains Alcon (NYSE:ALC) with a Equal-Weight and lowers the price target from $90 to $78.
- benzinga.com Wells Fargo Maintains Overweight on Alcon, Lowers Price Target to $86 Wells Fargo analyst Larry Biegelsen maintains Alcon (NYSE:ALC) with a Overweight and lowers the price target from $97 to $86.
- benzinga.com Mizuho Maintains Outperform on Alcon, Lowers Price Target to $85 Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $95 to $85.
- benzinga.com Baird Maintains Outperform on Alcon, Lowers Price Target to $90 Baird analyst Jeff Johnson maintains Alcon (NYSE:ALC) with a Outperform and lowers the price target from $98 to $90.
- benzinga.com Alcon Q1 2026 Earnings Call Transcript
- benzinga.com Alcon Raises FY2026 Adj EPS Guidance from $3.35-$3.44 to $3.38-$3.47 vs $3.38 Est; Affirms FY2026 Sales Guidance of $10.835B-$11.041B vs $11.117B Est Alcon (NYSE:ALC) raises FY2026 Adj EPS guidance from $3.35-$3.44 to $3.38-$3.47 vs $3.38 analyst estimate. Affirms FY2026 sales outlook from $10.835 billion-$11.041 billion to $10.835 billion-$11.041…
- benzinga.com Alcon Q1 Adj. EPS $0.85 Beats $0.81 Estimate, Sales $2.685B Miss $2.712B Estimate Alcon (NYSE:ALC) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.81 by 4.94 percent. This is a 16.44 percent increase over earnings of $0.73 per share…
benzinga.com Earnings Scheduled For May 5, 2026 
benzinga.com LENSAR Stock Plunges—Alcon Scraps Merger After Prolonged Regulatory Review Alcon cancels $356 million LENSAR merger due to regulatory delays and FTC opposition, adding pressure on shares.- benzinga.com LENSAR Agrees To Terminate Merger Agreement With Alcon Research LENSAR, Inc. (NASDAQ:LNSR) ("LENSAR" or the "Company"), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, announced that it reached an…
benzinga.com What Analysts Are Saying About Alcon Stock